• SNAI1–PIK3R2/p-EphA2 Axis in Thymic Tumors

  2026-09-01

  This 2024 study identifies SNAI1 as a transcriptional hub that promotes epithelial–mesenchymal transition, invasion, and cancer stem cell-like properties in thymic epithelial tumors. Multi-omics and functional experiments connect SNAI1 to a PIK3R2/p-EphA2 signaling axis and provide a mechanistic framework for investigating aggressive thymic tumor biology.

• Chlorin e6 Workflows for PDT Research

  2026-09-01

  Chlorin e6 enables controllable ROS-based experiments in anticancer photodynamic therapy and antibacterial wound scaffolds. This practical guide connects formulation, light dosimetry, assay design, and troubleshooting with findings from an aligned silk-fibroin platform.

• Chemistry of Silybin: Structure and Research Utility

  2026-08-31

  Křen and colleagues provide a comprehensive chemistry-focused review of silybin, tracing its isolation, stereochemical assignment, separation, synthesis, and systematic derivatization. The study’s practical value lies in showing how structural definition and chemical modification can improve interpretation of flavonolignan research, especially when complex Silymarin mixtures are used in biological assays.

• (S)-(+)-Ibuprofen: Reliable Cell Assays

  2026-08-31

  A scenario-based guide to using (S)-(+)-Ibuprofen as a defined COX inhibitor in cell viability, proliferation, and cytotoxicity workflows. It explains dosing, solvent compatibility, interpretation, protocol controls, and vendor-selection considerations for SKU B1018.

• Firefly Luciferase mRNA: Assay Workflow Guide

  2026-08-30

  Build more reproducible transfection, gene expression, and cell viability workflows with an ARCA-capped, modified reporter transcript. Learn how to connect bench-scale luminescence controls with LNP delivery and in vivo imaging decisions without confusing reporter output with biological effect.

• PreScission Protease (PSP): Tag Cleavage Guide

  2026-08-29

  PreScission Protease (PSP), SKU K1101, provides sequence-specific removal of fusion tags from recombinant proteins during purification. It is intended for substrates containing the defined HRV 3C protease cleavage site and is not a general-purpose protease for proteins lacking that sequence. The workflow should be performed under cold, compatible buffer conditions, with cleavage time and enzyme loading established empirically for each fusion construct.

• Y-27632 ROCK Inhibitor Workflow for Gastruloids

  2026-08-28

  Y-27632 enables reversible ROCK1/2 inhibition in workflows that connect cytoskeletal remodeling with gastruloid formation, imaging, and single-construct profiling. This guide translates a microraft-array study of euploid, aneuploid, and mosaic human pluripotent stem cell models into practical dosing, assay-design, and troubleshooting decisions.

• PPARγ, Macrophage Polarization, and DSS Colitis

  2026-08-28

  The reference study identifies PPARγ activation as a regulator of M1/M2 macrophage balance in dextran sulfate sodium-induced intestinal inflammation, linking this effect to opposing STAT-1 and STAT-6 phosphorylation. Its combined cell and mouse experiments connect macrophage phenotype, epithelial barrier integrity, and clinical disease features, while also defining important limits for translating findings beyond acute experimental colitis.

• DMG-PEG2000-NH2 in LNP Linker Workflows

  2026-08-27

  DMG-PEG2000-NH2 is an NH2-PEG derivative for controlled amide coupling, lipid nanoparticle (LNP) formulation, and surface-functionalized liposome development. This practical guide connects reagent handling, conjugation design, siRNA encapsulation considerations, and assay-based troubleshooting without overstating evidence from unrelated disease-model studies.

• Anlotinib Hydrochloride: An Assay-First Framework

  2026-08-27

  Anlotinib hydrochloride is a multi-target tyrosine kinase inhibitor that enables a more rigorous way to connect receptor phosphorylation with angiogenic phenotypes. This assay-first framework shows how to distinguish VEGFR2, PDGFRβ, and FGFR1 effects from downstream ERK convergence in cancer research.

• Thiamet G: From O-GlcNAc to Assay Logic

  2026-08-26

  Thiamet G is a selective O-GlcNAcase inhibitor for controlling protein O-GlcNAcylation in cellular and animal models. This guide connects its pharmacology with Wnt-driven osteogenesis and provides a framework for distinguishing target engagement from downstream phenotypes.

• Abiraterone Acetate in 3D Prostate Models

  2026-08-26

  Abiraterone acetate offers translational researchers a mechanistically defined CYP17 inhibitor for interrogating androgen biosynthesis in patient-derived prostate cancer models. By combining compound rigor with three-dimensional spheroid biology, researchers can distinguish target engagement from model-specific resistance and build more informative preclinical workflows.

• Cy3 NHS ester (non-sulfonated): Practical Guide

  2026-08-25

  Cy3 NHS ester (non-sulfonated) supports covalent orange-fluorescent labeling of accessible amino groups on proteins, peptides, and amino-modified oligonucleotides. It is suited to workflows that can tolerate DMSO or DMF, but should not be selected for water-only labeling or biomolecules that are highly sensitive to organic co-solvents.

• EAGLE-2 and EAGLE-3: Gepotidacin in UTI

  2026-08-25

  The EAGLE-2 and EAGLE-3 phase 3 trials showed that oral gepotidacin was non-inferior to nitrofurantoin for uncomplicated urinary tract infection and superior in one of the two studies. Their principal innovation was clinical evaluation of a first-in-class antibiotic that targets bacterial type II topoisomerases through a distinct binding site, offering a potential option when resistance limits established therapies.

• Aloin A and B Inhibit SARS-CoV-2 PLpro In Vitro

  2026-08-24

  The reference study identified aloin A and aloin B as selective in vitro inhibitors of both the proteolytic and deubiquitinating activities of SARS-CoV-2 papain-like protease (PLpro), while sparing 3CLpro. Its paired enzyme assays, structural modeling, and molecular dynamics simulations provide a mechanistic framework for evaluating oral-rinse ingredients, but the findings do not establish clinical antiviral efficacy.

8120 records 3/542 page Previous Next 12345 下5页 Last page